Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma

Phase 2WithdrawnNCT01151748

Stanford University

Overview

Phase II study of selective intra-arterial infusion of chemotherapy for intraocular retinoblastoma

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Retinoblastoma Eye Cancer

Interventions

Intra-arterial infusion of chemotherapyPROCEDURE

Eligibility

Sex: ALLMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients diagnosed with advanced intraocular retinoblastoma (International Retinoblastoma Classification group D or E\*). 2. Patients with tumor recurrence or vitreous seeding following completion of systemic chemotherapy or previous radiation therapy. Exclusion Criteria: 1. Congenital brain anomaly identified on MRI. 2. History of systemic coagulopathy. 3. Evidence of extra ocular retinoblastoma on clinical examination or neuroimaging.

Locations (1)

Stanford University School of Medicine

Stanford, California, United States

Outcomes

Primary Outcomes

Response: Globe salvage rate (Eyes saved/Eyes treated). This will be determined by clinical ocular examination.

Time frame: Follow-up will be performed for one year from treatment date.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.